We also found that PSGL-1 blockade resulted in a 1.6-fold higher frequency of tumor-infiltrating CD3+ cells and 30% higher expression of CD69 on intratumoral CD8+ T cells, indicating increased activation of these cells (Fig. 5D). The gene discussed is CD69; the disease is neoplasm.